Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, PlaceboControlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19

Thumbnail
View/ Open

Show full item record
Author
Cook, Paul P.; Jones, Rosie S.
URI
http://hdl.handle.net/10342/11742
Subject
 Acute respiratory distress syndrome; Angiopoietin 2; COVID-19 
Date
2022
Citation:
APA:
Cook, Paul P., & Jones, Rosie S.. (January 2022). Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, PlaceboControlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. , (), - . Retrieved from http://hdl.handle.net/10342/11742

Display/Hide MLA, Chicago and APA citation formats.

MLA:
Cook, Paul P., and Jones, Rosie S.. "Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, PlaceboControlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19". . . (), January 2022. December 02, 2023. http://hdl.handle.net/10342/11742.
Chicago:
Cook, Paul P. and Jones, Rosie S., "Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, PlaceboControlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19," , no. (January 2022), http://hdl.handle.net/10342/11742 (accessed December 02, 2023).
AMA:
Cook, Paul P., Jones, Rosie S.. Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, PlaceboControlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. . January 2022; (): . http://hdl.handle.net/10342/11742. Accessed December 02, 2023.
Collections